X L.P. Canaan Sells 164,747 Shares of Protagonist Therapeutics Inc (PTGX) Stock

Protagonist Therapeutics Inc (NASDAQ:PTGX) major shareholder X L.P. Canaan sold 164,747 shares of the company’s stock in a transaction on Wednesday, May 16th. The stock was sold at an average price of $6.42, for a total transaction of $1,057,675.74. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Major shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

X L.P. Canaan also recently made the following trade(s):

  • On Monday, May 14th, X L.P. Canaan sold 77,591 shares of Protagonist Therapeutics stock. The shares were sold at an average price of $6.37, for a total transaction of $494,254.67.
  • On Thursday, March 22nd, X L.P. Canaan sold 39,518 shares of Protagonist Therapeutics stock. The shares were sold at an average price of $20.61, for a total transaction of $814,465.98.
  • On Monday, March 19th, X L.P. Canaan sold 20,365 shares of Protagonist Therapeutics stock. The shares were sold at an average price of $20.55, for a total transaction of $418,500.75.
  • On Tuesday, March 13th, X L.P. Canaan sold 1,204 shares of Protagonist Therapeutics stock. The stock was sold at an average price of $20.84, for a total transaction of $25,091.36.
  • On Thursday, March 15th, X L.P. Canaan sold 13,155 shares of Protagonist Therapeutics stock. The stock was sold at an average price of $20.66, for a total transaction of $271,782.30.

PTGX opened at $5.99 on Friday. The stock has a market cap of $136.76 million, a P/E ratio of -2.87 and a beta of 3.54. Protagonist Therapeutics Inc has a twelve month low of $6.34 and a twelve month high of $6.50.

Protagonist Therapeutics (NASDAQ:PTGX) last released its quarterly earnings data on Wednesday, May 9th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.29) by ($0.07). The firm had revenue of $10.78 million during the quarter, compared to the consensus estimate of $10.70 million. analysts expect that Protagonist Therapeutics Inc will post -0.98 EPS for the current fiscal year.

Several institutional investors have recently bought and sold shares of PTGX. Wells Fargo & Company MN boosted its holdings in shares of Protagonist Therapeutics by 60.8% during the 3rd quarter. Wells Fargo & Company MN now owns 9,565 shares of the company’s stock worth $169,000 after buying an additional 3,617 shares in the last quarter. Bank of Montreal Can raised its position in Protagonist Therapeutics by 1,086.0% in the 4th quarter. Bank of Montreal Can now owns 5,930 shares of the company’s stock valued at $123,000 after buying an additional 5,430 shares during the last quarter. Schwab Charles Investment Management Inc. raised its position in Protagonist Therapeutics by 46.2% in the 4th quarter. Schwab Charles Investment Management Inc. now owns 19,300 shares of the company’s stock valued at $402,000 after buying an additional 6,100 shares during the last quarter. Acadian Asset Management LLC purchased a new stake in Protagonist Therapeutics in the 4th quarter valued at $197,000. Finally, First Manhattan Co. increased its position in shares of Protagonist Therapeutics by 2,408.2% during the 4th quarter. First Manhattan Co. now owns 416,364 shares of the company’s stock valued at $8,660,000 after purchasing an additional 399,764 shares during the last quarter. Hedge funds and other institutional investors own 56.00% of the company’s stock.

Several research firms have weighed in on PTGX. BidaskClub upgraded shares of Protagonist Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, March 3rd. Stifel Nicolaus initiated coverage on shares of Protagonist Therapeutics in a research note on Monday, January 29th. They set a “buy” rating and a $32.00 price objective on the stock. Zacks Investment Research lowered shares of Protagonist Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Friday, May 11th. Finally, BMO Capital Markets reaffirmed an “outperform” rating and issued a $13.00 price target (down previously from $42.00) on shares of Protagonist Therapeutics in a research note on Monday, March 26th. They noted that the move was a valuation call. Two analysts have rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating to the stock. Protagonist Therapeutics has a consensus rating of “Hold” and a consensus price target of $26.75.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc is a clinical-stage biopharmaceutical company with a peptide technology platform focused on discovering and developing new chemical entities (NECs) to address significant unmet medical needs. The Company’s product pipeline includes PTG-100, PTG-200 and PTG-300. Its primary focus is on developing oral peptide drugs that target biological pathways also targeted by marketed injectable antibody drugs.

Insider Buying and Selling by Quarter for Protagonist Therapeutics (NASDAQ:PTGX)

Receive News & Ratings for Protagonist Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply